Cambridge Investment Research Advisors Inc. Takes $45,000 Position in CalciMedica Inc. (NASDAQ:CALC)

Cambridge Investment Research Advisors Inc. purchased a new stake in CalciMedica Inc. (NASDAQ:CALC) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 23,539 shares of the company’s stock, valued at approximately $45,000. Cambridge Investment Research Advisors Inc. owned 0.17% of CalciMedica at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CALC. Stonepine Capital Management LLC purchased a new stake in shares of CalciMedica in the 4th quarter valued at approximately $1,660,000. Alyeska Investment Group L.P. purchased a new stake in shares of CalciMedica in the 4th quarter valued at approximately $1,318,000. Deerfield Management Company L.P. Series C grew its stake in shares of CalciMedica by 30.0% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,300,000 shares of the company’s stock valued at $4,602,000 after buying an additional 300,000 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of CalciMedica in the 4th quarter valued at approximately $153,000. Finally, Corient Private Wealth LLC purchased a new stake in shares of CalciMedica in the 4th quarter valued at approximately $135,000.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of CalciMedica in a report on Thursday, May 15th.

CalciMedica Stock Performance

Shares of CALC stock opened at $2.05 on Wednesday. The firm’s 50 day moving average price is $1.75 and its 200-day moving average price is $2.10. The company has a debt-to-equity ratio of 0.79, a quick ratio of 5.66 and a current ratio of 5.66. CalciMedica Inc. has a one year low of $1.42 and a one year high of $5.97. The firm has a market cap of $28.64 million, a P/E ratio of -1.31 and a beta of 1.24.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. As a group, equities research analysts predict that CalciMedica Inc. will post -2.21 EPS for the current year.

CalciMedica Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.